Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors

计划入组 102 人 · 首次发布于 2020 年 8 月 20 日

A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

计划入组 30 人 · 首次发布于 2023 年 1 月 6 日

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

计划入组 117 人 · 首次发布于 2020 年 2 月 5 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

Solid Biosciences Inc.

United States

Yichang Humanwell Oral Solid Dosage Plant

China

Arvinas

United States

FDA Grants Priority Review to Enhertu for HER2-Positive Metastatic Solid Tumors

EXUMA Biotech Reports Promising Phase 1 Results for Novel HER2-Targeted CAR-T Therapy in Solid Tumors

HER2-Directed ADCs Expand Treatment Spectrum Across Solid Tumors